Vol 60, No 1 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

Changes in cardiac adrenergic nervous system after transmyocardial laser revascularisation assessed by I-123-MIBG SPECT. A preliminary report

Anna Teresińska, Marian Śliwiński, Stefania Konieczna, Bożenna Szumilak, Maria Szymańska, Artur Dębski, Piotr Hendzel, Zbigniew Juraszyński
Kardiol Pol 2004;60(1):21-25.
Vol 60, No 1 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Background: Metaiodobenzylguanidine (MIBG), a noradrenaline analogue which may be labelled with I-123, has been used in the assessment of pre-synaptic activity of the cardiac adrenergic nervous system (Systadren) in several diseases. The effects of transmyocardial laser revascularisation (TMLR) on Systadren have not yet been established.
Aim: To examine whether TMLR-induced changes in Systadren may be one of the mechanisms responsible for clinical improvement in patients undergoing this method of revascularisation.
Methods: The study group consisted of 19 patients (mean age 63±9 years) who underwent TMLR, by using high-power CO2 laser; as a single method of cardiac revascularisation. Systadren was assessed before TMLR (STUDY-0), soon after the procedure (mean 13±5 days, STUDY-I), and in 12 patients six months after TMLR (STUDY-II). In total, 50 studies using I-123-MIBG SPECT were performed. The regional distribution of tracer was assessed qualitatively, using a 17-segment model of the left ventricle.
Results: In 16% of examinations the assessment of the I-123-MIBG uptake was not possible due to the poor quality of images. Thus, 41 SPECT studies (16 - STUDY-0, 16 - STUDY-I, and 9 - STUDY-II) were analysed and compared. In STUDY-0, an impaired uptake of I-123-MIBG was found in 193 of 272 analysed segments. In STUDY-I, the I-123-MIBG uptake increased in 5% of defects (CI0,95=3-9%) and deteriorated in 55% (CI0,95=48-62%). When STUDY-II was compared with baseline, the uptake was increased in 25% of defects (CI0,95=17-34%) and decreased in further 25% of defects. When STUDY-II was compared with STUDY-I, the uptake increased in 67% (CI0,95=58-75%) of defects and did not deteriorate in any. The global MIBG uptake in STUDY-I decreased in 15 patients (94%, CI0,95=70-100%) when compared with baseline, and increased in all 9 patients with long-term follow-up data available, when STUDY-II to STUDY-I was compared.
Conclusions: TMLR significantly deteriorates Systadren activity which, however, improves 6 months after the procedure to the values similar to those assessed pre-operatively. TMLR-induced impairment of Systadren may contribute to the clinical improvement observed shortly (<6 months) after the procedure.

Abstract

Background: Metaiodobenzylguanidine (MIBG), a noradrenaline analogue which may be labelled with I-123, has been used in the assessment of pre-synaptic activity of the cardiac adrenergic nervous system (Systadren) in several diseases. The effects of transmyocardial laser revascularisation (TMLR) on Systadren have not yet been established.
Aim: To examine whether TMLR-induced changes in Systadren may be one of the mechanisms responsible for clinical improvement in patients undergoing this method of revascularisation.
Methods: The study group consisted of 19 patients (mean age 63±9 years) who underwent TMLR, by using high-power CO2 laser; as a single method of cardiac revascularisation. Systadren was assessed before TMLR (STUDY-0), soon after the procedure (mean 13±5 days, STUDY-I), and in 12 patients six months after TMLR (STUDY-II). In total, 50 studies using I-123-MIBG SPECT were performed. The regional distribution of tracer was assessed qualitatively, using a 17-segment model of the left ventricle.
Results: In 16% of examinations the assessment of the I-123-MIBG uptake was not possible due to the poor quality of images. Thus, 41 SPECT studies (16 - STUDY-0, 16 - STUDY-I, and 9 - STUDY-II) were analysed and compared. In STUDY-0, an impaired uptake of I-123-MIBG was found in 193 of 272 analysed segments. In STUDY-I, the I-123-MIBG uptake increased in 5% of defects (CI0,95=3-9%) and deteriorated in 55% (CI0,95=48-62%). When STUDY-II was compared with baseline, the uptake was increased in 25% of defects (CI0,95=17-34%) and decreased in further 25% of defects. When STUDY-II was compared with STUDY-I, the uptake increased in 67% (CI0,95=58-75%) of defects and did not deteriorate in any. The global MIBG uptake in STUDY-I decreased in 15 patients (94%, CI0,95=70-100%) when compared with baseline, and increased in all 9 patients with long-term follow-up data available, when STUDY-II to STUDY-I was compared.
Conclusions: TMLR significantly deteriorates Systadren activity which, however, improves 6 months after the procedure to the values similar to those assessed pre-operatively. TMLR-induced impairment of Systadren may contribute to the clinical improvement observed shortly (<6 months) after the procedure.
Get Citation

Keywords

cardiac adrenergic system - i-123-mibg - metaiodobenzylguanidine - spect - transmyocardial laser revascularisation

About this article
Title

Changes in cardiac adrenergic nervous system after transmyocardial laser revascularisation assessed by I-123-MIBG SPECT. A preliminary report

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 60, No 1 (2004)

Pages

21-25

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2004;60(1):21-25.

Keywords

cardiac adrenergic system - i-123-mibg - metaiodobenzylguanidine - spect - transmyocardial laser revascularisation

Authors

Anna Teresińska
Marian Śliwiński
Stefania Konieczna
Bożenna Szumilak
Maria Szymańska
Artur Dębski
Piotr Hendzel
Zbigniew Juraszyński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl